Background
==========

The G12/13 subfamily of heterotrimeric guanine nucleotide binding proteins (G proteins) is comprised of two α-subunits in mammals, Gα~12~ and Gα~13~, that have been implicated in a variety of physiological and pathological cellular responses that include proliferation, cytoskeletal rearrangements, migration, and metastatic invasion \[[@B1],[@B2]\]. A diverse set of putative effector proteins have been identified as direct interactors with one or both G12/13 subfamily members; however, the roles of individual Gα-effector interactions in specific cellular responses remain largely undefined \[[@B3]\]. The most extensively characterized G12/13 target proteins are a subset of Rho-specific guanine nucleotide exchange factors (RhoGEFs) that activate the monomeric G protein Rho via tandem Dbl-homology/pleckstrin-homology domains \[[@B4]\]. The Rho monomeric GTPases are known primarily for their role in regulating actin cytoskeletal dynamics, but these proteins also mediate cell polarity, microtubule dynamics, membrane transport pathways, transcription factor activity, cell growth, and tumorigenesis \[[@B5]\]. The G12/13-RhoGEF-Rho axis mediates critical signaling and developmental pathways in model organisms that include *Drosophila melanogaster*\[[@B6]\], *Caenorhabditis elegans*\[[@B7]\], and zebrafish \[[@B8]\]. In addition, direct interaction with RhoGEFs is required for mutationally activated Gα~12~ to trigger increased invasiveness of breast cancer cells \[[@B9]\].

Activated G12/13 α-subunits trigger Rho activation via binding and stimulation of three distinct RhoGEFs: p115RhoGEF, LARG and PDZ-RhoGEF \[[@B10]-[@B13]\]. This interaction is mediated primarily by a domain, located near the N-terminus of each RhoGEF, that is closely related to the regulator of G protein signaling (RGS) domain that defines the growing family of RGS proteins \[[@B14],[@B15]\]. Although p115RhoGEF, LARG and PDZ-RhoGEF are highly similar in this "RGS homology" (RH) domain \[[@B16]\], these proteins appear to be activated by different mechanisms and play non-redundant roles in G12/13 subfamily-mediated signaling. Purified p115RhoGEF binds Gα~12~ and Gα~13~ and accelerates GTPase activity for both proteins, but only Gα~13~ can stimulate p115RhoGEF to activate RhoA *in vitro*\[[@B10],[@B17]\]. Interaction of Gα~12~ or Gα~13~ with purified LARG can trigger its activation of RhoA; however, stimulation by Gα~12~ requires prior phosphorylation of LARG by the nonreceptor tyrosine kinase Tec \[[@B13]\]. Furthermore, studies utilizing small interfering RNA to hinder expression of specific RhoGEFs show that LARG is a specific downstream effector of thrombin receptor-mediated signaling, whereas signaling through the lysophosphatidic acid (LPA) receptor is attenuated by blocking PDZ-RhoGEF expression \[[@B18]\]. These results are compelling in light of a separate report that the thrombin receptor shows preferential coupling to Gα~12~, whereas the LPA receptor preferentially utilizes Gα~13~ as a conduit to downstream signaling \[[@B19]\]. Although it is possible that Gα~12~ stimulates a post-translationally modified form of p115RhoGEF or PDZ-RhoGEF in cells, the evidence to date suggests LARG as the most likely RhoGEF serving as a physiological effector for Gα~12~. Gains in our understanding of the specificity of RhoGEF engagement within the G12/13 subfamily should provide insights into the non-overlapping functions of Gα~12~ and Gα~13~ in signal transduction.

Crystallographic studies have revealed important structural aspects of the interaction between Gα~13~ and the RH domain of p115RhoGEF, including numerous residues in both proteins that provide contact points \[[@B20],[@B21]\]. Initially, purification of Gα~13~ for crystallography required that it be engineered as a chimera in which amino acid sequence within several regions, including the N- and C-termini, was replaced by corresponding sequence from the Gi subfamily protein Gαi~1~\[[@B20]\]. The structure of the Gα~13~:p115RhoGEF-RH complex was later refined in crystallographic studies that utilized a Gα~13~ chimera harboring Gαi~1~ sequence only at the N-terminus. Because the Gα N-terminus was unstructured in this crystallized complex, any role of this region in RhoGEF interaction remains to be determined. Although the region of Gα~13~ downstream of the Switch III region harbors several residues critical for RhoGEF engagement, notably Glu^273^, Thr^274^, Asn^278^, and Arg^279^ within the α~3~ helix and α~3~-β~5~ loop, other regions closer to the Gα~13~ C-terminus do not emerge in the crystal structure as providing key RhoGEF contact points \[[@B21]\].

In contrast to Gα~13~, a structure of Gα~12~ in complex with a RhoGEF target has not been reported, although a chimeric Gα~12~ harboring the N-terminus of Gαi~1~ has been crystallized \[[@B22]\]. To examine the full sequence of Gα~12~ for structural features mediating its interaction with RhoGEFs, we engineered a series of cassette substitutions within constitutively activated Gα~12~ and examined these variants for *in vitro* binding to the RH domains of LARG and p115RhoGEF, as well as ability to drive the Rho-dependent process of serum response element (SRE) mediated transcription in cells \[[@B23]\]. Our results reveal unexpected regions of Gα~12~ as harboring determinants of its functional interaction with RhoGEFs, and also identify key charged amino acids near the Gα~12~ N-terminus that may confer selective binding to LARG.

Results
=======

Myc-tagged Gα~12~ retains RhoGEF binding, Rho-mediated signaling, and conformational activation
-----------------------------------------------------------------------------------------------

To identify mutants of Gα~12~ impaired in RhoGEF binding, we first sought to establish an *in vitro* system in which Gα~12~ mutants could be expressed ectopically in cultured cells, rendered soluble in a detergent extract, and detected without interference from endogenous Gα~12~. We engineered the constitutively active Gln^229^Leu variant of Gα~12~ (Gα~12~^QL^) to harbor a myc epitope tag, flanked by linkers of the sequence SGGGGS and positioned between residues Pro^139^ and Val^140^. This insertion site was chosen due to its approximate alignment with the position of green fluorescent protein in Gαq in a prior study \[[@B24]\]. We expressed myc-tagged and untagged Gα~12~^QL^ in HEK293 cells, prepared detergent-soluble extracts, and analyzed these by immunoblotting. As shown in Figure [1](#F1){ref-type="fig"}A, myc-tagged Gα~12~^QL^ was detected by both anti-myc and anti-Gα~12~ antibodies, with the latter generating a much stronger signal while avoiding an off-target 37 kDa band detected in all samples by the anti-myc antibody. Also, the myc-tagged protein (\~45 kDa) was readily discernible from endogenous Gα~12~ and untagged Gα~12~^QL^ (\~43 kDa). Next, we subjected myc-Gα~12~^QL^ to pulldown experiments using an immobilized GST fusion of the p115RhoGEF RH domain, as described in Methods. Myc-tagged and untagged Gα~12~^QL^ bound to p115-RH with similar affinity (Figure [1](#F1){ref-type="fig"}B), and comparison with mock-transfected cells indicated the \~45 kDa band detected by anti-Gα~12~ was dependent on transfection with the myc-Gα~12~^QL^ plasmid. Furthermore, LARG-RH and p115-RH showed similar ability to co-precipitate myc-tagged Gα~12~^QL^ (Figure [1](#F1){ref-type="fig"}C). To ascertain that myc-Gα~12~ is functional as a mediator of cellular signal transduction through Rho, we measured transcriptional activation of a luciferase reporter gene positioned downstream of the serum response element (SRE), a component of the c-fos promoter that provides a readout of Gα~12~-mediated Rho activation \[[@B23]\]. Myc-tagged and untagged Gα~12~^QL^ exhibited similar ability to stimulate this response in HEK293 cells co-transfected with SRE-luciferase (Figure [1](#F1){ref-type="fig"}D). Furthermore, trypsin digestion of HEK293 cell lysates harboring myc-Gα~12~^QL^ yielded a protected fragment of \~40 kDa, comparable to results observed previously with GTPγS-loaded, purified Gα~12~\[[@B25]\]. An inactive, constitutively GDP-bound (Gly^228^Ala) variant of myc-tagged Gα~12~ did not yield this \~40 kDa fragment when digested with trypsin (Figure [1](#F1){ref-type="fig"}E). Taken together, these results suggest myc-Gα~12~^QL^ undergoes conformational activation and retains normal signaling through the RhoGEF:Rho pathway. Because of the superior sensitivity of anti-Gα~12~ antibody in detecting myc-Gα~12~^QL^, and the easily discernible gel shift of Gα~12~ caused by the myc tag and linkers (see Figures [1](#F1){ref-type="fig"}A and B), we chose to utilize anti-Gα~12~ to detect myc-Gα~12~^QL^ in subsequent protein binding experiments.

![**Effector binding and conformational activation of myc-tagged, constitutively activated Gα**~**12**~**.** Molecular weight markers (in kDa) are indicated at right of panels where applicable. All results shown are representative of two or more independent experiments. (**A**) Expression and solubilization of Gα~12~^QL^ (*12*^*QL*^) and myc-tagged Gα~12~^QL^ (*myc-12*^*QL*^) transiently expressed in HEK293 cells. Cells transfected with the vector pcDNA3.1 are included as a negative control (*vector*). Detergent-soluble extracts were prepared by high-speed centrifugation and subjected to SDS-PAGE and immunoblotting, using either anti-myc (Zymed) or anti-Gα~12~ (Santa Cruz Biotechnology) antibodies as described in Methods. (**B**) *In vitro* binding of myc-tagged and untagged Gα~12~^QL^ by p115RhoGEF. HEK293 cells extracts containing myc-Gα~12~^QL^ were subjected to protein interaction assays (see Methods) using an immobilized GST fusion of the RH domain of p115RhoGEF (*RGS*) or GST alone (*GST*). Samples were washed, separated by SDS-PAGE, and analyzed by immunoblotting using antibodies described above. (**C**) Specificity of myc-Gα~12~^QL^ detection in interaction assays. HEK293 cells transfected with either myc-Gα~12~^QL^ (*myc-12*^*QL*^) or the empty pcDNA3.1 plasmid (*vect*) were lysed and assayed for binding to GST fusions of the RH domain of p115RhoGEF (*p115*) or LARG, or GST alone (*GST*). Immunoblot analysis was performed using anti-Gα~12~ antibody as described above. (**D)** Serum response element (SRE) luciferase activation by myc-Gα~12~^QL^. HEK293 cells grown in 12-well plates were co-transfected with the plasmids SRE-L (0.2 μg) and pRL-TK (0.02 μg), plus 0.1 μg of the plasmid indicated on the X-axis. Y-axis values show firefly luciferase signal normalized for *Renilla* luciferase signal within each sample. (**E**) Trypsin protection assays of myc-tagged Gα~12~. Lysates from HEK293 cells transfected with myc-Gα~12~^QL^ (*myc-12*^*QL*^) or the constitutively GDP-bound Gly^228^Ala mutant of wildtype Gα~12~ (*myc-12*^*G228A*^) were subjected to trypsin digests as described in Methods. Immunoblot analysis was performed using J169 antibody \[[@B25]\] at 1:700 dilution.](1750-2187-8-3-1){#F1}

Mutations that uncouple Gα~12~ from RhoGEF binding and Rho-mediated signaling
-----------------------------------------------------------------------------

To scan Gα~12~ for regions participating in its interaction with RhoGEFs, we utilized a comprehensive panel of mutants in which sextets of consecutive amino acids in myc-Gα~12~^QL^ are replaced by the sextet Asn-Ala-Ala-Ile-Arg-Ser (Figure [2](#F2){ref-type="fig"} shows the native amino acid sextet and alphabetical designation for each mutant). This strategy of "NAAIRS" cassette substitutions was chosen due to prediction of this motif being tolerated in the three-dimensional structure of proteins \[[@B26]\], prior use of this approach in mapping functional regions of both retinoblastoma and the telomerase catalytic subunit \[[@B27],[@B28]\], and our previous success employing this strategy to identify Gα~12~ determinants of binding to the scaffolding subunit of protein phosphatase-2A and the cytoplasmic tail of polycystin-1 \[[@B29],[@B30]\]. Variants of Gα~12~ were expressed in HEK293 cells and tested for interaction with immobilized LARG-RH, as described in Methods. As shown in Figure [3](#F3){ref-type="fig"}, myc-Gα~12~^QL^ was co-precipitated by a GST fusion of LARG-RH but not by GST alone. Many of these cassette mutants yielded a moderate-to-robust signal in the LARG-precipitated fraction; however, a subset displayed a weak or absent signal (Figure [3](#F3){ref-type="fig"}). To assess impairment of LARG binding for each myc-Gα~12~^QL^ variant, we quantified the band intensity for each precipitated sample (*pulldown*), and divided this by the band intensity in the starting cellular extract (*load*). These calculations generated a "pulldown:load ratio" for each mutant, and also for the positive control myc-Gα~12~^QL^ that was tested in each experiment. Nearly all cassette mutants were solubilized by our detergent conditions and detected by immunoblotting; exceptions were mutant *W*, which we did not engineer due to overlap with the insertion site of the myc tag (see Figure [2](#F2){ref-type="fig"}), and mutant *CC* due to low expression levels that produced inconclusive results (data not shown). As shown in Table [1](#T1){ref-type="table"}, the majority of cassette mutants exhibited pulldown:load ratios greater than 40% of the ratio determined for myc-Gα~12~^QL^. However, a number of mutants exhibited lower pulldown:load ratios (\<20% of positive control) with a subset generating a ratio less than 10% of the positive control. For all samples, precipitation by immobilized GST yielded no Gα~12~ signal (Figure [3](#F3){ref-type="fig"}), indicating these mutants were not merely binding the GST-glutathione-sepharose complex nor forming insoluble aggregates under these *in vitro* conditions. Also, we examined the full panel of Gα~12~ cassette mutants for interaction with a GST fusion of the N-terminal 252 amino acids of p115RhoGEF (p115-RH). None of the LARG binding-impaired mutants (those with pulldown:load ratio \<20% of positive control; see Table [1](#T1){ref-type="table"}) yielded a signal intensity in the p115-RH precipitate that exceeded 50% of intensity for the positive control myc-Gα~12~^QL^ (data not shown).

![**Residues replaced in Gα**~**12**~**cassette mutants.** For each mutant, designated in italics (*A*-*Z*, *AA*-*ZZ*, *AAA*-*KKK*), the native amino acid sextet replaced by the sequence Asn-Ala-Ala-Ile-Arg-Ser is shown. An arrow between Pro^139^ and Val^140^ indicates the site of myc tag insertion. Mutant *W* was not produced. The dashed box indicates the native Gln^229^ mutated to Leu to render Gα~12~ constitutively active. The native residues replaced in mutant *KKK* are Lys-Asp-Ile-Met-Leu-Gln and thus partially overlap with mutant *JJJ*. All cassette mutants contain the activating Q^229^L mutation, except mutant *LL* due to its cassette substitution.](1750-2187-8-3-2){#F2}

![**In vitro interaction of Gα**~**12**~**mutants with LARG.** Immunoblot results for all LARG binding-impaired Gα~12~ cassette mutants and selected other mutants are shown. HEK293 cells were transfected with the indicated plasmids (7.0 μg per 10-cm plate) and lysates were prepared for co-precipitation assays as described in Methods. Prior to this step, 5% of each lysate was set aside as starting material (*load*). Pulldown experiments were performed on 7--9 mutants per experiment, plus myc-Gα~12~^QL^ as a positive control, using equal amounts of GST-LARG-RH (*LARG*) immobilized on glutathione-sepharose. Immobilized GST was utilized in parallel as a negative control. For all experimental samples, 20% of the volume was analyzed by SDS-PAGE and Coomassie blue staining to verify equal amounts of GST-LARG-RH and GST proteins in the precipitates (data not shown). Immunoblots displayed in this figure are representative of at least three trials per cassette mutant, except for mutants *A*-*D*, *F*-*H*, *V*, and *KKK* that showed minimal impairment in LARG binding after two trials. (**Inset)** Coomassie blue analysis of GST-fusion constructs expressed in bacteria and immobilized on glutathione-sepharose: GST-LARG-RH (*LARG*), GST-p115-RH (*p115*), and GST alone. Molecular weight standards (in kDa) are indicated at right.](1750-2187-8-3-3){#F3}

###### 

**Gα**~**12**~**cassette mutants impaired in binding LARG-RH**

  --------- ----------------------------------------------------------
  70-100%    A-D F-H L N O T-V X BB DD-FF II KK XX YY BBB DDD III-KKK
  40-70%                       H P GG JJ WW ZZ CCC
  20-40%                             Y AA PP
  10-20%                       I OO QQ-SS UU VV FFF
  0-10%            E J K M Q R S Z HH LL-NN TT AAA EEE GGG HHH
  N/D                                  W CC
  --------- ----------------------------------------------------------

Cassette substitution mutants of myc-Gα~12~^QL^ (see Figure [2](#F2){ref-type="fig"} for alphabetical designations) were expressed in HEK293 cells and subjected to protein interaction assays using a GST-fusion of the RH domain of LARG as described in Methods, and for each mutant a pulldown:load ratio was determined and calculated as a percent (left column) of the same ratio for unmodified myc-Gα~12~^QL^ assayed in parallel. Each Gα~12~ mutant was analyzed in three independent experiments, except for mutants that appeared in the 70-100% category in two independent experiments.

The Gα~12~ cassette mutant designated *OO* was among those impaired in LARG binding, consistent with our previous work demonstrating its uncoupling from Rho-mediated signaling \[[@B31]\], and several other cassette substitutions within the Switch regions disrupted binding to LARG (mutants *HH*, *LL*, *MM*, *NN*, *QQ*, and *RR*; see Figure [2](#F2){ref-type="fig"}). However, impaired LARG binding also was caused by substitutions in other regions of Gα~12~ (Table [1](#T1){ref-type="table"}). Prior crystallographic studies identified several residues in Gα~13~ that serve as contact points with p115-RH \[[@B20],[@B21]\]. Table [2](#T2){ref-type="table"} lists Gα~13~ residues identified as contact points with p115-RH in these earlier studies, and indicates the corresponding Gα~12~ cassette mutant for each Gα~13~ residue. From our *in vitro* binding results (Table [1](#T1){ref-type="table"}), it is apparent that most Gα~12~ mutants corresponding to RhoGEF-contacting Gα~13~ residues displayed partial or severe impairment of LARG binding, mutants *V, BB* and *DDD* being exceptions. However, several RhoGEF-uncoupling substitutions in Gα~12~ (cassette mutants *E, I, J, K, M*, *Z, NN, OO, VV, AAA, EEE, FFF, GGG* and *HHH*) replaced amino acids that do not correspond to Gα~13~ contacts with p115-RH. Gα~12~ mutants *J* and *K* replaced sections of the P-loop, a motif critical in guanine nucleotide binding, and thus would be predicted as impaired in signaling. However, our finding of RhoGEF-uncoupling mutations at the N- and C-termini of Gα~12~ was unexpected, because these regions either lacked corresponding contact points in the Gα~13~:p115-RH complex or were disordered in the G12/13 crystal structures (i.e. the N-terminus). To determine whether these N- and C-terminal mutations in Gα~12~ are impaired in Rho-mediated signaling, we expressed these variants in HEK293 cells and measured stimulation of SRE-luciferase transcription. All N- and C-terminal mutants impaired in RhoGEF binding were poor activators of this reporter gene (Figure [4](#F4){ref-type="fig"}A). Several cassette mutants in the N- and C-terminal regions of Gα~12~ that displayed normal binding to LARG (mutants *F, V,* and *KKK*) stimulated SRE-luciferase in a manner comparable to the myc-Gα~12~^QL^ positive control (Figure [4](#F4){ref-type="fig"}A). With the exception of mutant *VV*, immunoblot analysis of HEK293 cell lysates revealed expression levels of these mutants similar to myc-Gα~12~^QL^ (Figure [4](#F4){ref-type="fig"}B).

###### 

**Gα**~**12**~**cassette mutants corresponding to rgRGS contact points within Gα**~**13**~

   **Gα**~**13**~**residues in contact with p115-RH**   **myc-Gα**~**12**~^**QL**^**NAAIRS mutant**
  ---------------------------------------------------- ---------------------------------------------
                        Val^98^                                              Q
                   Asp^101^, Ala^102^                                        R
                   Lys^105^, Leu^106^                                        S
                   Thr^127^, Arg^128^                                        V
                        Phe^168^                                            BB
              Arg^200^, Pro^202^, Lys^204^                                  HH
                        Gln^226^                                            LL
              Arg^230^, Lys^231^, Phe^234^                                  MM
                        Met^257^                                            QQ
                        Arg^260^                                            RR
                        Asn^270^                                            SS
         Ile^271^, Glu^273^, Thr^274^, Ile^275^                             TT
              Asn^278^, Arg^279^, Val^280^                                  UU
                        Arg^335^                                            DDD

Gα~13~-native residues previously identified as providing contact points with the RH domain of p115RhoGEF \[[@B20],[@B21]\] are indicated in the left column. Cassette mutants ("NAAIRS" substitution) in which the homologous residue(s) within Gα~12~ have been altered are indicated in the right column. See Figure [2](#F2){ref-type="fig"} for Gα~12~ mutant designations.

![**Activation of serum response element mediated transcription by Gα12 mutants.**(**A**) Luciferase reporter assay results of selected cassette mutants. HEK293 cells grown in 12-well plates were co-transfected with the plasmids SRE-L (0.2 μg) and pRL-TK (0.02 μg), plus 1.0 μg of the plasmid encoding each cassette mutant indicated on the X-axis. Firefly luciferase values were normalized for *Renilla* luciferase values within each sample, and values are presented as a percent of the value calculated for myc-Gα~12~^QL^ (Y-axis) within the same experiment. Mutationally active (*12QL*) and inactive (*G228A*) samples were analyzed in parallel. Results shown are a representative of two experiments performed per Gα~12~ variant. (**B**) Expression level of Gα~12~ mutants. A sample of each lysate was set aside prior to luminometry and analyzed by SDS-PAGE and immunoblotting using anti-Gα~12~ antibody (Santa Cruz Biotechnology). For all samples, densitometric intensity was determined as described in Methods, then divided by positive control myc-Gα~12~^QL^ levels within the same experiment, and SRE-L/*Renilla* values were adjusted to reflect this normalization for protein levels.](1750-2187-8-3-4){#F4}

Conformational activation of RhoGEF-uncoupled Gα~12~ mutants
------------------------------------------------------------

A concern in our experimental approach was that specific "NAAIRS" cassette substitutions could cause global disruption of Gα~12~ shape, so that a mutant might fail to assume an activated conformation. For RhoGEF-uncoupled Gα~12~ mutants at the N-terminus (i.e. upstream of the P-loop) and C-terminus, we measured protection against trypsin proteolysis. Exchange of GDP for the activating GTP on Gα proteins triggers a conformational change that conceals a trypsin cleavage site within the Switch II region; this property allows the activated state of the Gα protein to be revealed by resistance to trypsin \[[@B25],[@B32]\]. As shown in Figure [5](#F5){ref-type="fig"}A, mutants *E*, *I*, and *HHH* yielded a protected fragment of approximately 40 kDa that matched the fragment observed following tryptic digestion of myc-Gα~12~^QL^. Results for mutant *AAA* were difficult to interpret; a band of slightly smaller size than undigested *AAA* was generated by tryptic digestion, but it was unclear whether this matched the \~40 kDa trypsin-protected fragment in myc-Gα~12~^QL^. Other C-terminal mutants we tested− *VV, EEE*, *FFF*, and *GGG*− appeared to match the constitutively inactive myc-Gα~12~^G228A^ which lacked this \~40 kDa fragment (Figure [5](#F5){ref-type="fig"}A). These results suggest several C-terminal mutants of Gα~12~ were sufficiently distorted in shape by the "NAAIRS" substitution to allow trypsin access to proteolytic sites normally not exposed in the GTP-bound state. However, cassette mutants *E* and *I* at the N-terminus and *HHH* at the C-terminus appeared to maintain an activated conformation despite their impairment in RhoGEF binding and SRE stimulation.

![**Conformational efficacy of N-terminal and C-terminal Gα**~**12**~**mutants uncoupled from RhoGEFs.** (**A**) Trypsin protection of selected Gα~12~ mutants. HEK293 cell lysates expressing the indicated variants of myc-Gα~12~^QL^, or unmodified myc-Gα~12~^QL^ (*12*^*QL*^), or the G^228^A variant of myc-Gα~12~ (12^*G228A*^) were subjected to trypsin protection assays as described in Methods. Samples were incubated 20 min at 30°C in the presence (**+**) or absence (**−**) of TPCK-treated trypsin, and were analyzed by SDS-PAGE and immunoblotting using J169 antibody (1:700 dilution). Small horizontal arrows indicate position of the trypsin-protected fragment in selected lanes. Data presented are representative of two or more independent experiments per sample. (**B**) Specificity of uncoupling in selected Gα~12~ variants. For each cassette mutant of myc-Gα~12~^QL^ (indicated at top), interaction with each Gα~12~ target (indicated at left) was quantified as a pulldown:load ratio as described in Methods, and was calculated as a percent of the identical ratio determined for myc-Gα~12~^QL^ within the same experiment. Values are indicated as follows: (**++**) = \>60%, (**+**) = 20 to 60%, (−) = 0 to 20%. Interacting proteins are GST fusions of the following: RH domain of LARG (*LARG*), C-terminal 107 amino acids of heat shock protein-90 alpha (*Hsp90*), protein phosphatase-5 (*PP5*), scaffolding Aα subunit of protein phosphatase-2A (*PP2A*), C-terminal 98 amino acids of E-cadherin (*E-cad*). Values presented indicate the mean of two or more trials per interaction sample.](1750-2187-8-3-5){#F5}

We also tested whether RhoGEF-uncoupled cassette mutants at the N- and C-termini of Gα~12~ could interact *in vitro* with other reported binding partners: heat shock protein-90, protein phosphatase-5, the scaffolding Aα subunit of protein phosphatase-2A, and the cytoplasmic tail of E-cadherin \[[@B33]-[@B36]\]. As shown in Figure [5](#F5){ref-type="fig"}B, each mutant displayed pulldown:load ratios \>60% of the positive control, myc-Gα~12~^QL^, for at least two of these non-RhoGEF targets. Taken as a whole, these findings reveal a subset of mutations at the N- and C-terminus that selectively uncouple Gα~12~ from RhoGEFs while preserving conformational activation and ability to bind other downstream proteins.

We next visualized the position of these RhoGEF-interacting regions in the crystal structure of a Gα~12~ chimera in which the N-terminal 48 residues were replaced by the N-terminus of Gαi~1~\[[@B22]\]. The native region of Gα~12~ replaced in cassette mutant *E* is not ordered in this structure; however, the regions replaced in the C-terminal mutants *EEE-HHH* are highlighted (Figure [6](#F6){ref-type="fig"}). The sextet replaced in mutant *HHH* (highlighted in black) resides in the α~5~ helix that extends along the Gα~12~ surface and approaches the C-terminus at the top of the diagram.

![**Structural position of Gα**~**12**~**C-terminal determinants of RhoGEF binding.** The structure of N-terminally Gαi~1~-substituted Gα~12~ (PDB accession code 1ZCA, \[[@B22]\]) as a GDP•AlF~4~^**¯**^ activated complex was analyzed using PyMOL software. The native Gα~12~ region substituted for the sequence "NAAIRS" in the C-terminal mutants *EEE*, *FFF*, and *GGG* is highlighted in orange, and the sextet substituted in mutant *HHH* is highlighted in black. The bound GDP molecule is highlighted in blue. Figure was rendered in The PyMOL Molecular Graphics System, Version 1.5.0.1 Schrödinger, LLC.](1750-2187-8-3-6){#F6}

Differential uncoupling of Gα~12~ from LARG and p115RhoGEF
----------------------------------------------------------

We next sought to identify specific residues within these N- and C-terminal sextets of Gα~12~ that mediate RhoGEF interaction. To examine putative surface residues, we performed charge substitutions in the native regions corresponding to cassette mutants *E*, *I*, and *HHH*, and examined these variants for SRE-luciferase activation. None of the single-residue charge-reversals in the regions encompassed in mutants *I* or *HHH* caused significant decrease in SRE signaling (data not shown). However, a double charge-reversal in the mutant *E* region, converting Glu^31^ and Glu^33^ to Arg residues, caused a near-complete loss of SRE activation in HEK293 cells despite normal levels of protein expression (Figure [7](#F7){ref-type="fig"}A). We next examined this Gα~12~ mutant, designated Glu^31/33^Arg, for binding to the RH domains of LARG and p115RhoGEF. As shown in Figure [7](#F7){ref-type="fig"}B, a selective loss of RhoGEF binding was observed: the Glu^31/33^Arg charge-reversals severely disrupted LARG-RH binding relative to non-mutated myc-Gα~12~^QL^ (pulldown:load ratio \~18% of control) but had minimal effect on p115-RH binding (ratio \~86% of control). In trypsin protection assays, the Glu^31/33^Arg mutant yielded a protected fragment at the same molecular weight (\~40 kDa) as observed for the myc-Gα~12~^QL^ positive control, suggesting its ability to attain an activated conformation (Figure [7](#F7){ref-type="fig"}C). The intermediate intensity of this band (approximately a midpoint between activated Gα~12~ and the constitutively inactive Gly^228^Ala variant) may be due in part to the mutational introduction of Arg residues providing additional sites for trypsin proteolysis. Taken as a whole, these findings not only provide evidence that the structurally uncharacterized N-terminus of Gα~12~ plays a role in its functional interaction with RhoGEFs, but also reveal individual charged residues in this region as candidates for conferring specificity of Gα~12~ for LARG among the RH-containing RhoGEFs.

![**Selective RhoGEF uncoupling by N-terminal charge substitutions in Gα**~**12**~**.**(**A**) Luciferase reporter gene assays. Cassette mutant *E* (see Figure [2](#F2){ref-type="fig"}) and the double charge substitution mutant Glu^31/33^Arg were compared to myc-Gα~12~^QL^ (*12*^*QL*^) in SRE-luciferase assays under the cell transfection conditions described in Figure [4](#F4){ref-type="fig"}. A constitutively GDP-bound variant of wildtype myc-Gα~12~ (*12*^*G228A*^) was assayed in parallel as a negative control. Results shown are the mean of three independent experiments, and error bars indicate range. (**B**) Protein-protein interaction assays. Detergent-soluble extracts from transfected HEK293 cells transfected with myc-Gα~12~^QL^, the Glu^31/33^Arg mutant, or empty pcDNA3.1 plasmid (*vector*) were subjected to co-precipitation assays as described in Methods, using GST-fusions of either LARG-RH (*LARG*), p115RhoGEF-RH (*p115*), the N-terminal domain of the Gα~12~ target radixin \[[@B46]\], or no adduct (*GST*). Prior to the precipitation step, 5% of each lysate was set aside as starting material (*load*). Table values show the pulldown:load ratio for Glu^31/33^Arg as a percent of the positive control value (*12*^*QL*^), with mean +/- range presented for three independent experiments. (**C**) Trypsin protection of the Glu^31/33^Arg mutant, in comparison to constitutively GTP- and GDP-bound Gα~12~. Assays were performed as described in Methods. Results shown are representative of two independent experiments.](1750-2187-8-3-7){#F7}

Discussion
==========

The G12 subfamily members Gα~12~ and Gα~13~ are well-documented as utilizing RhoGEFs as downstream signaling effectors. Crystallographic studies by Chen et al. \[[@B20]\] and Hajicek et al. \[[@B21]\] have provided intricate structural details of the interaction between Gα~13~ and the RH domain of p115RhoGEF, identifying a set of Gα~13~ residues that directly contact this target protein. The structure of Gα~12~ also has been elucidated, using a chimera comprised of amino acids 49--379 of Gα~12~ preceded by amino acids 1--28 of Gαi~1~\[[@B22]\]. However, a Gα~12~:RhoGEF complex has not been reported. In the current study, we utilized *in vitro* and cell-based approaches to examine the interaction between Gα~12~ and two putative target RhoGEFs, LARG and p115RhoGEF. Using immobilized RGS-homology (RH) domains of these RhoGEFs, we identified several substitutions of native amino acids in Gα~12~ that disrupted its binding to these proteins and blocked its ability to stimulate the Rho-dependent process of SRE-mediated transcription. Although our results indicated that a number of common determinants in Gα~12~ and Gα~13~ mediate RhoGEF binding, several RhoGEF-uncoupling mutations in Gα~12~ did not correspond to regions of RhoGEF contact within Gα~13~; these include amino acid sextet substitutions in the C-terminal α~5~ helix as well as the structurally uncharacterized N-terminus. Several of these Gα~12~ mutants exhibited protection from tryptic digestion as well as unimpeded binding to other, non-RhoGEF targets, indicating their impaired interaction with RhoGEFs is not caused by failure to attain an activated conformation and suggesting the shapes of other effector-binding surfaces in these Gα~12~ mutants remain intact as RhoGEF interaction is disrupted.

Although Gα~12~ and Gα~13~ share 67% amino acid identity and bind several common downstream targets, several functional differences between these Gα proteins suggest their signaling mechanisms are not redundant \[[@B1],[@B3]\]. Both Gα~12~ and Gα~13~ bind LARG and p115RhoGEF \[[@B10],[@B12]\], and both of these RhoGEFs accelerate GTPase activity of purified Gα~12~ and Gα~13~ in single-turnover assays \[[@B13],[@B17]\]. Whereas Gα~13~ stimulates both p115RhoGEF and LARG to trigger guanine nucleotide exchange on RhoA *in vitro*, Gα~12~ can only stimulate LARG under these experimental conditions, and in a manner dependent on prior phosphorylation of LARG by the tyrosine kinase Tec \[[@B10],[@B13]\]. Also, activated Gα~12~ is more potent than Gα~13~ in recruiting the RH domain of p115RhoGEF to the plasma membrane, and specific mutations in p115RhoGEF disrupt Gα~12~ but not Gα~13~ in triggering this localization \[[@B37]\]. At the cellular and organismal levels, it is increasingly clear that Gα~12~ and Gα~13~ utilize non-overlapping signaling pathways. Mice lacking Gα~13~ die early in embryogenesis due to defects in vascular development and thrombin-induced cell migration, but mice lacking Gα~12~ do not display these developmental defects. However, knockout of Gα~12~ combined with absence of Gα~13~ causes earlier lethality than Gα~13~ knockout alone, and in mice lacking one Gα~13~ allele, at least one Gα~12~ allele must be present for normal embryonic development \[[@B38],[@B39]\]. Furthermore, LPA-induced activation of mTOR complex 2 leading to activation of PKC-δ requires Gα~12~ but not Gα~13~\[[@B40]\]. Because of these differences, plus the increasing list of Gα~12~-specific effector proteins (including another RhoGEF, AKAP-Lbc, that is activated exclusively by Gα~12~ within the G12/13 subfamily), we believe the Gα~12~:RhoGEF interface cannot be defined summarily by structural features of the Gα~13~:RhoGEF complex.

Among the Gα~13~ residues that provide contact points with p115RhoGEF in crystallographic studies \[[@B20],[@B21]\], many have corresponding residues within Gα~12~, and therefore we paid particular attention to Gα~12~ cassette mutants corresponding to these key Gα~13~ residues (see Table [2](#T2){ref-type="table"}). For example, the Gα~12~ mutant *HH* replaced residues corresponding to Gα~13~ residues Arg^200^, and Lys^204^, both of which provide contact points with p115-RH. In another Gα~12~ cassette mutant, termed *RR,* a substituted residue corresponds to Arg^260^ within Gα~13~; this residue provides a key contact with amino acids within the βN-αN region of p115RhoGEF. Also, Gα~12~ cassette mutants *Q, R,* and *S* contain altered residues in the Gα~12~ helical domain that correspond to p115-RH interacting residues in Gα~13~. Among the Gα~12~ mutants corresponding to p115-RH contact points in Gα~13~, most showed impaired RhoGEF interaction and poor stimulation of SRE-mediated signaling. However, several differences between Gα~12~ and Gα~13~ were noted, particularly in the helical domain. Gα~12~ cassette mutant *V* alters residues that correspond to two contact points within the Gα~13~:p115-RH complex; however, this mutant showed minimal impairment in RhoGEF binding *in vitro* and stimulated SRE-mediated transcription robustly in cells. Gα~12~ mutant *BB*, which removes a Phe corresponding to a Gα~13~ contact point with p115-RH, displayed a slight impairment in SRE-mediated transcriptional activation and no impairment of RhoGEF binding. In addition, Gα~13~ utilizes a C-terminal residue (Arg^335^) as a contact point with p115-RH, but the corresponding Gα~12~ cassette mutant (*DDD*) exhibited normal binding to RhoGEFs and only modest impairment in SRE signaling. However, because this cassette mutant preserves the corresponding Arg residue in Gα~12~ (DRKR[R]{.ul}N substituted for NAAI[R]{.ul}S), it is possible this Arg in Gα~12~ participates in RhoGEF binding despite the alteration in adjacent amino acids.

Aside from the N- and C-terminal mutants of Gα~12~ that show impaired RhoGEF binding, we have identified other RhoGEF-uncoupling mutations in Gα~12~ that lack corresponding Gα~13~ contact points for p115-RH (see Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). None of the native Gα~12~ residues replaced in cassette mutants *M* and *Z* match p115-RH contact points in Gα~13~, and thus may indicate Gα~12~-specific determinants of RhoGEF interaction. Impaired RhoGEF binding also was observed in Gα~12~ mutants *J* and *K*; however, this most likely was due to these substitutions disrupting the canonical GXGXXGKS guanine nucleotide binding motif \[[@B41]\]. Although our results suggest a core similarity in the mechanisms utilized by Gα~12~ and Gα~13~ to engage RhoGEF targets, it is apparent that several determinants of RhoGEF binding are unique to Gα~13~. We have identified determinants that may be unique to Gα~12~ or potentially important for both G12/13 subfamily members in RhoGEF engagement. Studies of Gα~13~ variants harboring corresponding mutations will be important in distinguishing these possibilities.

A role for the C-terminus of G12/13 subfamily proteins in RhoGEF engagement has been suggested by prior studies. Kreutz et al. \[[@B42]\] engineered chimeras of Gα~12~ and Gα~13~ that were interchanged downstream of the Switch III region, and demonstrated the C-terminal 114 amino acids of Gα~13~ as sufficient for its unique ability to stimulate purified p115RhoGEF to activate RhoA. Also, a chimeric Gα~13~ in which the region downstream of Switch III was replaced by the corresponding region of Gαi~2~ displayed loss of ability to stimulate SRE-mediated transcriptional activation \[[@B43]\]. Initial crystallographic studies of Gα~13~:RhoGEF interaction utilized a chimeric Gα~13~ harboring Gαi~1~ sequence at the C-terminus, and determinants of RhoGEF binding were not found downstream of the Switch regions in this protein \[[@B20]\]. Subsequent crystallographic work utilizing Gα~13~ with native C-terminal sequence did identify residues slightly downstream of the Switch III region as critical for RhoGEF engagement \[[@B21]\], and also revealed a more distal residue in the C-terminal region (Arg^335^) as providing a contact point with the RH domain of p115RhoGEF. However, no residues at the extreme C-terminus of Gα~13~, including the α~5~ helix, were found to mediate RhoGEF binding. Our results suggest differences between Gα~12~ and Gα~13~ in the role of the C-terminus, as several substitutions near the extreme C-terminus of Gα~12~ disrupted RhoGEF interaction, most notably the cassette mutant *HHH* within the α~5~ helix.

The N-terminus provides the greatest amino acid sequence divergence between Gα~12~ and Gα~13~. Gα subunits utilize this region for interaction with Gβγ \[[@B44]\], and in Gα~12~ and Gα~13~ this region confers specificity of coupling to thrombin and LPA receptors, respectively \[[@B19]\]. Importantly, Gα~13~ is a more potent stimulator of RhoGEF activation *in vitro* than a chimeric Gα~13~ harboring the N-terminus of Gαi~1~, indicating a possible role of the Gα~13~ N-terminus in RhoGEF activation \[[@B21]\]. However, specific determinants within the N-terminus of G12/13 subfamily proteins that mediate binding to effectors, including RhoGEFs, have not been reported. The 48-residue region at the N-terminus of Gα~12~ has not been characterized in crystallographic studies, because its replacement by the Gαi~1~ N-terminus was necessary for obtaining sufficient quantities of purified protein \[[@B16],[@B22]\]. Furthermore, the N-terminus was disordered in crystallographic analysis of both the aforementioned Gαi~1~/Gα~13~ hybrid and a more recent structure of full-length Gα~13~\[[@B21]\], suggesting the Gα~12~ N-terminus may be refractory to crystallographic analysis even if native sequence is utilized. Our approach of employing cassette substitution mutants throughout the length of Gα~12~ has provided an indirect means of circumventing this obstacle, and has revealed specific N-terminal regions as possible determinants of RhoGEF interaction. Importantly, our discovery that mutations in this N-terminal region (cassette mutants *E* and *I*) cause loss of RhoGEF binding allowed us to focus on putative surface residues in these substituted regions, ultimately revealing Glu^31^ and Glu^33^ as critical for Gα~12~ interaction with LARG and stimulation of SRE-mediated transcription. Our finding that charge substitutions of these N-terminal Gα~12~ residues disrupted binding to the LARG-RH domain but had minimal effect on interaction with the corresponding domain of p115RhoGEF was intriguing, and suggested these residues play a role in targeting Gα~12~ preferentially to LARG. It is possible that Gα~12~ harbors sufficient RhoGEF-interacting surfaces for *in vitro* binding to p115RhoGEF, but that a functional, physiological interaction (i.e. with LARG) requires this N-terminal region. Our RhoGEF binding results for Gα~12~ cassette mutant *E*, as well as the more specific Glu^31/33^Arg mutant, were surprising in light of earlier findings that RhoGEF binding was preserved in a Gα~12~ chimera containing the Gαi~1~ N-terminus \[[@B22]\]. It is possible that "NAAIRS" substitution and particularly the Glu^31/33^Arg charge-reversals cause a more dramatic change to this RhoGEF binding surface than occurs when Gαi~1~ sequence is introduced. Cassette mutant *E* and the Glu^31/33^Arg mutant are impaired in activating the Rho-dependent readout of SRE-mediated transcriptional activation in cells, and it remains to be determined whether the Gαi~1~/Gα~12~ chimera is similarly impaired in stimulating this pathway.

Because previous phosphorylation of LARG by Tec is a requirement for Gα~12~, but not Gα~13~, for *in vitro* activation of Rho, it will be important to determine whether this phosphorylation event regulates interaction of LARG with Gα~12~, particularly its N-terminus and C-terminal α~5~ helix. Furthermore, as suggested by Hajicek et al. \[[@B21]\], it is conceivable that post-translational modification of p115RhoGEF in cells modulates its responsiveness to Gα~13~ or could potentially render it a target of Gα~12~. A challenge for future studies of Gα~12~- and Gα~13~-mediated signaling will be to determine the combinations of G12/13 subfamily α-subunits and RhoGEFs that activate Rho in response to different signaling inputs, and in different cell and tissue types.

Conclusions
===========

Gα~12~ and Gα~13~ define the G12/13 class of heterotrimeric G protein α-subunits, which participate in numerous signaling pathways through stimulation of RhoGEFs that subsequently activate Rho. Although these proteins are non-redundant in their stimulation of effectors and their cellular and organismal roles, only Gα~13~ has been characterized in the structural basis of its interaction with RhoGEF targets. However, the involvement of Gα~12~ in stimulating SRE-mediated transcription, cell rounding, c-Jun N-terminal kinase activation, cell growth, and metastatic invasion supports a physiological role for a Gα~12~-RhoGEF-Rho axis in developmental pathways and disease progression \[[@B45]\]. Therefore, an improved understanding of the structural aspects of Gα~12~:RhoGEF interaction likely will be of broad importance. Our results provide several key additions to this structural model: 1) characterization of the Gα~12~:RhoGEF interacting surface by identifying regions in Gα~12~ that mediate binding; 2) unexpected roles of the Gα~12~ N-terminal region and C-terminal α~5~ helix in engagement of RhoGEFs; 3) identification of specific residues near the Gα~12~ N-terminus that may mediate its selectivity for LARG as an effector protein. To date, no structural studies have examined the interaction of Gα~12~ with RhoGEFs. Our hope is that mutant-based strategies will augment such crystallographic approaches and provide key details toward understanding the structural aspects and biological role of this Gα:effector interaction.

Methods
=======

DNA constructs
--------------

Plasmids encoding 1) a fusion of glutathione-S-transferase (GST) to amino acids 320--606 of LARG (GST-LARG-RH), and 2) amino acids 1--252 of p115RhoGEF with an N-terminal myc epitope tag were kindly provided by Tohru Kozasa (Univ. of Ill., Chicago). We used PCR to subclone the p115RhoGEF sequence into pGEX-2T (GE Healthcare) to produce GST-p115-RH. All "NAAIRS" amino acid substitution mutants within myc-tagged Gα~12~ Gln^229^Leu (myc-Gα~12~^QL^) were engineered as described previously \[[@B29]\]. Single amino acid substitutions were engineered in myc-Gα~12~^QL^ using the QuikChange II® site-directed mutagenesis system (Agilent Technologies), and this system was used to engineer a constitutively inactive Gly^228^Ala variant (myc-Gα~12~^G228A^) within a plasmid encoding myc-tagged, wildtype Gα~12~ (provided by Pat Casey, Duke University). The luciferase reporter plasmid SRE-L was a gift from Channing Der (University of North Carolina Chapel Hill).

Expression and immobilization of GST fusion proteins
----------------------------------------------------

GST fusion constructs were transformed into BL21(Gold)-DE3 cells (Stratagene). Cells were grown under 75 μg/ml ampicillin selection to OD~600~ of 0.5−0.7, and recombinant protein expression was induced using 0.5 mM isopropyl-β-D-thiogalactopyranoside (Fisher Scientific). After 3 h, cells were lysed on ice using 0.32 mg/ml lysozyme (MP Biomedicals), and GST fusion proteins were bound to glutathione-sepharose 4B (GE Healthcare) as described previously \[[@B31],[@B34]\]. Following three washes in 50 mM Tris pH 7.7 supplemented with 1 mM EDTA, 1 mM dithiothreitol, and 150 mM NaCl, samples were snap-frozen in aliquots and stored at −80°C.

Preparation of detergent-soluble extracts harboring Gα~12~ mutants
------------------------------------------------------------------

Human embryonic kidney cells (HEK293) were grown in Dulbecco's modified Eagle medium (Mediatech, Manassas, VA) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), penicillin and streptomycin. For myc-Gα~12~^QL^ and each of its 62 NAAIRS substitution mutants (see Figure [2](#F2){ref-type="fig"}), 7.0 μg of plasmid DNA was transfected into a 10-cm dish of HEK293 cells grown to approximate 90% confluence, using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. After 36--42 hours, cells were scraped from dishes, washed twice with phosphate-buffered saline, and solubilized in NAAIRS Lysis buffer (50 mM HEPES pH 7.5, 1 mM EDTA, 3 mM dithiothreitol, 10 mM MgSO~4~, 1% (w/v) polyoxyethylene-10-lauryl ether) containing the protease inhibitors 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (1.67 mM), leupeptin (2.1 μM), pepstatin (1.45 μM), TLCK (58 μM), TPCK (61 μM), and phenylmethylsulfonyl fluoride (267 μM). Samples were centrifuged at 80,000 *g* for 1 h, and supernatants were snap-frozen in 60-μl aliquots and stored at −80°C.

Protein interaction assays
--------------------------

HEK293 cell extracts were diluted in NAAIRS Lysis buffer lacking polyoxyethylene-10-lauryl ether, using sufficient volume to dilute this detergent in the samples to 0.05% (w/v). Next, sepharose-bound GST fusion proteins were added and allowed to incubate for approximately 2 h at 4°C with continuous inversion. A percentage of the diluted extract was set aside as starting material prior to sepharose addition. Next, samples were centrifuged at 1,300 *g*, and pellets were washed three times and then subjected to SDS-PAGE and immunoblot analysis using an antibody specific to the Gα~12~ N-terminus (Santa Cruz Biotechnology) or the myc 9E10 epitope tag (Zymed), followed by alkaline phosphatase conjugated secondary antibodies (Promega). For each variant of myc-Gα~12~^QL^, the Gaussian intensity of the \~45 kDa band from the precipitated material and the corresponding band from the starting material were quantified using a Kodak Gel Logic 100 system equipped with Molecular Imaging 5.X software (Carestream Health, New Haven CT).

Reporter gene assays
--------------------

HEK293 cells grown in 12-well plates were transfected with 0.2 μg SRE-luciferase plasmid (encoding firefly luciferase) and 0.02 μg pRL-TK plasmid encoding *Renilla* luciferase, plus plasmids encoding variants of myc-Gα~12~^QL^. Reporter assays for SRE-mediated transcriptional activation were performed as described previously \[[@B31]\]. Briefly, cells were washed with phosphate-buffered saline and lysed in 1X passive lysis buffer (Promega), and lysates were analyzed using a Dual-luciferase assay system and GloMax 20/20 luminometer (Promega). Light output due to firefly luciferase activity was divided by output from *Renilla* luciferase activity to normalize samples for transfection efficiency.

Trypsin protection experiments
------------------------------

HEK293 cells grown in 10-cm dishes were transfected with various Gα~12~ constructs using Lipofectamine 2000 (Invitrogen), and tryptic digestions were performed as a modification of the procedure of Kozasa and Gilman \[[@B25]\]. Briefly, cells were lysed in 50 mM Hepes pH 8.0, 1 mM EDTA, 3 mM dithiothreitol, 1% polyoxyethylene-10-lauryl ether containing the same protease inhibitors as NAAIRS Lysis buffer (see above) but at two-fold lower concentration. Samples were cleared by centrifugation at 70,000 *g* for 1 h, and supernatants were diluted 20-fold in volume using 50 mM Hepes pH 8.0, 1 mM EDTA, 3 mM dithiothreitol, 10 mM MgSO~4~. Samples were digested with 10 μg/ml TPCK-treated trypsin (New England Biolabs) for 20 min at 30°C, and proteolysis was terminated by addition of 100 μg/ml lima bean trypsin inhibitor (Worthington, Lakewood NJ). Samples were analyzed by SDS-PAGE and immunoblotting using J169 antisera specific to the Gα~12~ C-terminus, provided by Tohru Kozasa (Univ. of Ill., Chicago).
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